Article Text

other Versions

PDF
New anticoagulant treatments to protect against stroke in atrial fibrillation
  1. Tatjana S Potpara1,2,
  2. Gregory YH Lip3,
  3. Stavros Apostolakis3
  1. 1Faculty of Medicine, University of Belgrade, Belgrade, Serbia
  2. 2Cardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia
  3. 3University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
  1. Correspondence to Stavros Apostolakis, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK; stavrosapos{at}hotmail.com

Abstract

Warfarin has long been the ‘gold standard’ of oral anticoagulation for stroke prevention in atrial fibrillation (AF). Recently, the oral direct thrombin inhibitors and direct factor Xa inhibitors have emerged as attractive alternatives to warfarin and have already changed the landscape of stroke prevention in AF. The new anticoagulants have important advantages over warfarin. Despite their impressive performance in clinical trials, their long-term efficacy and safety still require evaluation in ‘real-world’ clinical practice. In this review, the emerging role of the new oral anticoagulants for stroke prevention in patients with AF is discussed.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.